Completed NA INTERVENTIONAL 3-arm NCT05742438

Effects of Dexmedetomidine/Lidocaine/Intrathecal Morphine on Cancer Metastasis Biomarker After Colorectal Surgery

Effect of Dexmedetomidine Infusion, Lidocaine Infusion, and Intrathecal Morphine Injection on Biomarker for Perioperative Stress and Immune Response, and Cancer Progression and Metastasis in Colorectal Cancer Surgery

Sponsor: Korea Institute of Science and Technology

Conditions Anesthesia Cancer Metastatic Colorectal Cancer Inflammation

Interventions Dexmedetomidine IV Lidocaine IV intrathecal morphine

Updated 8 times since 2023 Last updated: Mar 27, 2025 Started: Apr 12, 2023 Primary completion: Jul 5, 2023 Completion: Aug 5, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This NA trial investigates Anesthesia and Cancer Metastatic and is currently completed. Korea Institute of Science and Technology leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed NA
May 2025 — Sep 2025 [monthly]

Completed NA
Sep 2024 — May 2025 [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Apr 2024 — Jul 2024 [monthly]

Completed NA

Status: Recruiting → Completed

▶ Show 3 earlier versions

Aug 2023 — Apr 2024 [monthly]

Recruiting NA

Status: Not Yet Recruiting → Recruiting
Apr 2023 — Aug 2023 [monthly]

Not Yet Recruiting NA
Mar 2023 — Apr 2023 [monthly]

Not Yet Recruiting NA

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Korea Institute of Science and Technology
Samsung Medical Center

Data source: Samsung Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea